Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2812-2819

  Farag, Sherif S ^a   George, Stephen L ^b   Lee, Edward J ^c   Baer, Maria ^d   Dodge, Richard K ^b   Becknell, Brian ^a   Fehniger, Todd ^a   Silverman, Lewis R ^e   Crawford, Jeffrey ^f   Bloomfield, Clara D ^a   Larson, Richard A ^g   Schiffer, Charles A ^h   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e MOUNT SINAI HOSPITAL   (United States)

^f DUKE CANCER INSTITUTE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; LIGAND; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENZYME BLOOD LEVEL; EOSINOPHILIA; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; INFECTION; INJECTION SITE; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN MANIFESTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; VOMITING;

ACUTE DISEASE; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; COMBINED MODALITY THERAPY; CYCLOSPORINS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FATIGUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC DISEASES; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID; LIFE TABLES; MIDDLE AGED; NAUSEA; NEOPLASM PROTEINS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036718432     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Intensive postremission chemotherapy in adults with acute leukemia
2. Dose intensification in acute myeloid leukemia: Greater effectiveness at lower cost-principal report of the Medical Research Council's AML9 study
3. Double induction strategy in AML comparing high with standard dose Ara-C: Hematotoxicity and antileukemic efficacy
4. A Phase III trial comparing idarubicin and daunorubicin combination with cytarabine in acute myeloid leukemia: A Southeastern Cancer Study Group study
5. Long-term survival in acute myeloid leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia
6. Prognostic significance of karyotype in de novo acute myeloid leukemia
7. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwestern Oncology Group study
8. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors
9. Natural killer cell-stimulated inhibition of growth of myeloid and lymphoid clonogenic leukemias
10. NK cell receptors
11. Paired inhibitory and triggering NK cell receptors for HLA class I molecules
12. Surface receptors delivering opposite signals regulate the function of human NK cells
13. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA
14. ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
15. The functional relationship of the interleukins
16. Cytotoxicity of interleukin 2 activated lymphocytes for leukemia and lymphoma cells
17. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity
18. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2
19. Lymphokine activated killer cell plus recombinant interleukin 2 therapy of erythroleukemia in mice
20. Interleukin 2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: Updated experience with 20 cases
21. A Phase II study of interleukin 2 in 49 patients with relapsed or refractory leukemia
22. Continuous intravenous infusion of high-dose recombinant interleukin 2 for acute myeloid leukemia-a Phase II study
23. Functional consequences of interleukin 2 receptor expression on resting lymphocytes. Identification of a novel natural killer subset with high-affinity receptors
24. Extended continuous infusion of low dose recombinant low dose interleukin 2 in advanced cancer: Prolonged immunomodulation without significant toxicity
25. Selective modulation of human natural killer cells in vivo after prolonged infusion of low-dose recombinant interleukin 2
26. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin 2 plus periodic intermediate dose pulsing
27. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
28. Parallel Phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B Study 9420
29. CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin 2 and c-kit ligand
30. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
31. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of non-epithelial origin
32. Nonparametric estimation from incomplete observations
33. Interleukin 2 bolus infusion as a late consolidation therapy in second remission of acute myeloblastic leukemia
34. Polyethylene glycolated interleukin 2 as maintenance therapy for acute myelogenous leukemia in second remission
35. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT)
36. Management of acute myeloid leukemia in elderly patients
37. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity
38. A pilot study of interleukin 2 for adult patients with acute myelogenous leukemia in first complete remission
39. Recombinant interleukin 2 for acute myeloid leukemia in first complete remission: A pilot study
40. Outpatient interleukin 2 (IL-2) following stem cell transplantation (SCT) increases NK cell number and cytotoxicity
41. Broad tumor associated expression and recognition by tumor-derived γ δ cells of MICA and MICB
42. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse